CD22 and acute lymphoblastic leukemia: developed CD22–CD19-bispecific CAR T cells and demonstrated the killing effect of CD19−CD22+ and CD19+CD22− B-ALL cell lines in vitro, as well as the significant B-ALL clearance in an NSG mouse model (99).